Maarten Lucas Donswijk

Dr. Maarten Lucas Donswijk

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in European Urology
Verified
Journal Article
Closed access
PDPaolo Dell’oGlio
Paolo Dell’oGlio
HVHielke M. de Vries
Hielke M. de Vries
EMElio Mazzone
Elio Mazzone
GKGijs H. KleinJan
Gijs H. KleinJan
MDMaarten Lucas Donswijk
Maarten Lucas Donswijk
OBOscar R. Brouwer
Oscar R. Brouwer

4 November 2019 in BJU International
Verified
Journal Article
Open access
PDF file
HLHenk B. Luiting
Henk B. Luiting
PLPim J. van Leeuwen
Pim J. van Leeuwen
MBMartijn B. Busstra
Martijn B. Busstra
TBTessa Brabander
Tessa Brabander
HPHenk G. van der Poel
Henk G. van der Poel
Monique RoobolMonique Roobol
Monique Roobol
Objectives: To review the literature to determine the sensitivity and specificity of gallium‐68 prostate‐specific membrane antigen ( 68 Ga‐PSMA) positron‐emission tomography (PET) for detecting pelvic lymph node metastases in patients with primary prostate cancer (PCa), and the positive predictive value in patients with biochemical recurrence (BCR) after initial curative treatment, and, in addition, to determine the detection rate and management impact of 68 Ga‐PSMA PET in patients with BCR after radical prostatectomy (RP). Materials and Methods: We performed a comprehensive literature search. Search terms used in MEDLINE, EMBASE and Science Direct were ‘(PSMA, 68 Ga‐PSMA, 68 Gallium‐PSMA, Ga‐68‐PSMA or prostate‐specific membrane antigen)’ and ‘(histology, lymph node, staging, sensitivity, specificity, positive predictive value, recurrence, recurrent or detection)’. Relevant abstracts were reviewed and full‐text articles obtained where possible. References to and from obtained articles were searched to identify further relevant articles. Results: Nine retrospective and two prospective studies described the sensitivity and specificity of 68 Ga‐PSMA PET for detecting pelvic lymph node metastases before initial treatment, which ranged from 33.3% to 100% and 80% to 100%, respectively. In eight retrospective studies, the positive predictive value of 68 Ga‐PSMA PET in patients with BCR before salvage lymph node dissection ranged from 70% to 100%. The detection rate of 68 Ga‐PSMA PET in patients with BCR after RP in the PSA subgroups <0.2 ng/mL, 0.2–0.49 ng/mL and 0.5 to <1.0 ng/mL ranged from 11.3% to 50.0%, 20.0% to 72.7% and 25.0% to 87.5%, respectively. Conclusion: The review results showed that 68 Ga‐PSMA PET had a high specificity for the detection of pelvic lymph node metastases in primary PCa. Furthermore, 68 Ga‐PSMA PET had a very high positive predictive value in detecting lymph node metastases in patients with BCR. By contrast, sensitivity was only moderate; therefore, based on the currently available literature, 68 Ga‐PSMA PET cannot yet replace pelvic lymph node dissection to exclude lymph node metastases. In the salvage phase, 68 Ga‐PSMA PET had both a high detection rate and impact on radiotherapy planning in early BCR after RP.

3 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ITInne J. Den Toom
Inne J. Den Toom
KBKoos Boeve
Koos Boeve
DLDaphne Lobeek
Daphne Lobeek
Elisabeth BloemenaElisabeth Bloemena
Elisabeth Bloemena
MDMaarten Lucas Donswijk
Maarten Lucas Donswijk
Remco De BreeRemco De Bree
Remco De Bree
Background: Sentinel lymph node biopsy (SLNB) has been introduced as a diagnostic staging modality for detection of occult metastases in patients with early stage oral cancer. Comparisons regarding accuracy to the routinely used elective neck dissection (END) are lacking in literature. Methods: A retrospective, multicenter cohort study included 390 patients staged by END and 488 by SLNB. Results: The overall sensitivity (84% vs. 81%, p = 0.612) and negative predictive value (NPV) (93%, p = 1.000) were comparable between END and SLNB patients. The END cohort contained more pT2 tumours (51%) compared to the SLNB cohort (23%) (p < 0.001). No differences were found for sensitivity and NPV between SLNB and END divided by pT stage. In floor-of-mouth (FOM) tumours, SLNB had a lower sensitivity (63% vs. 92%, p = 0.006) and NPV (90% vs. 97%, p = 0.057) compared to END. Higher disease-specific survival (DSS) rates were found for pT1 SLNB patients compared to pT1 END patients (96% vs. 90%, p = 0.048). Conclusion: In the absence of randomized clinical trials, this study provides the highest available evidence that, in oral cancer, SLNB is as accurate as END in detecting occult lymph node metastases, except for floor-of-mouth tumours.


5 April 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FBF. E. Buisman
F. E. Buisman
MHM. Y. V. Homs
M. Y. V. Homs
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
WFW. F. Filipe
W. F. Filipe
RBR. J. Bennink
R. J. Bennink
BKBas Groot Koerkamp
Bas Groot Koerkamp
Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk of intrahepatic recurrence. A large retrospective propensity score analysis demonstrated that HAIP chemotherapy is particularly effective in patients with low-risk oncological features. The aim of this randomized controlled trial (RCT) --the PUMP trial-- is to investigate the efficacy of adjuvant HAIP chemotherapy in low-risk patients with resectable CRLM. This is an open label multicenter RCT. A total of 230 patients with resectable CRLM without extrahepatic disease will be included. Only patients with a clinical risk score (CRS) of 0 to 2 are eligible, meaning: patients are allowed to have no more than two out of five poor prognostic factors (disease-free interval less than 12 months, node-positive colorectal cancer, more than 1 CRLM, largest CRLM more than 5 cm in diameter, serum Carcinoembryonic Antigen above 200 μg/L). Patients randomized to arm A undergo complete resection of CRLM without any adjuvant treatment, which is the standard of care in the Netherlands. Patients in arm B receive an implantable pump at the time of CRLM resection and start adjuvant HAIP chemotherapy 4–12 weeks after surgery, with 6 cycles of floxuridine scheduled. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival, hepatic PFS, safety, quality of life, and cost-effectiveness. Pharmacokinetics of intra-arterial administration of floxuridine will be investigated as well as predictive biomarkers for the efficacy of HAIP chemotherapy. In a side study, the accuracy of CT angiography will be compared to radionuclide scintigraphy to detect extrahepatic perfusion. We hypothesize that adjuvant HAIP chemotherapy leads to improved survival, improved quality of life, and a reduction of costs, compared to resection alone. If this PUMP trial demonstrates that adjuvant HAIP chemotherapy improves survival in low-risk patients, this treatment approach may be implemented in the standard of care of patients with resected CRLM since adjuvant systemic chemotherapy alone has not improved survival. The PUMP trial is registered in the Netherlands Trial Register (NTR), number: 7493 . Date of registration September 23, 2018.

1 June 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PMPieter D. de Veij Mestdagh
Pieter D. de Veij Mestdagh
IWIris Walraven
Iris Walraven
WVWouter V. Vogel
Wouter V. Vogel
WSWillem H. Schreuder
Willem H. Schreuder
EWErik van Werkhoven
Erik van Werkhoven
AAAbrahim Al-Mamgani
Abrahim Al-Mamgani